{"id":475360,"date":"2021-04-13T08:03:46","date_gmt":"2021-04-13T12:03:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/"},"modified":"2021-04-13T08:03:46","modified_gmt":"2021-04-13T12:03:46","slug":"biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/","title":{"rendered":"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone"},"content":{"rendered":"
\n

ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire<\/u><\/a> — BioCorRx Inc<\/strong><\/a>. (OTCQB: BICX) (\u201cBioCorRx\u201d or the \u201cCompany\u201d), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a clinical trial of BICX104, a naltrexone pellet implant for the treatment of Opioid Use Disorder (OUD). During prior nonclinical studies, several variations of BICX102 were evaluated and the current variation, BICX104, was selected for advancement to the IND stage.<\/p>\n

BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed in partnership with the National Institutes of Health (NIH) and the National Institute on Drug Abuse under\u00a0RFA DA-19-002, \u201cDevelopment of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3\/UH3) (Clinical Trial Optional)<\/a>.\u201d The Company had a previous pre-IND meeting with the FDA, at which time the FDA deemed the 505(b)(2) pathway acceptable. The Section 505(b)(2) regulatory pathway under the Federal Food, Drug and Cosmetic Act (the \u201cFFDCA\u201d) provides a potentially shortened regulatory approval window. The FDA also stated that the Company may seek eventual dual indication on the product for OUD and Alcohol Use Disorder (AUD).<\/p>\n

Bal Brar DVM, PhD, BioCorRx SVP of Drug Development and principal investigator for the NIDA funded research, stated, \u201cWe are very pleased to announce this regulatory submission of BICX104, a gradual release implantable pellet for opioid use disorder. This medication has the potential to save numerous lives afflicted by the opioid epidemic devastating the country.\u201d<\/p>\n

Brady Granier, President, and Director of BioCorRx, Inc., and CEO of BioCorRx Pharmaceuticals, Inc., stated, \u201cI want to thank all of our partners for helping us reach this milestone for our company. What we were able to achieve during a year of uncertainty with the coronavirus pandemic has been remarkable. We look forward to advancing BICX104 to the clinical phase upon IND clearance so that we can move closer to bringing this important medication to the masses. The opioid epidemic has unfortunately gotten worse since COVID-19 and we hope that BICX104 can soon be available to help those in need.\u201d<\/p>\n

According to\u00a0data provided<\/a>\u00a0by the Centers for Disease Control and Prevention (CDC), over 81,000 drug overdose deaths occurred in the U.S. between June 2019 and May 2020. This data represents the most overdose deaths ever recorded in a 12-month period and experts attribute this increase, at least in part, to the COVID-19 pandemic.<\/p>\n

\u201cWe\u2019ve been working tirelessly to advance our naltrexone pellet for several years now and with the help of NIDA, our partners and our shareholders, it\u2019s very exciting to be able to take this next step toward potential FDA approval,\u201d BioCorRx CEO, CFO and Director Lourdes Felix said. \u201cThe pandemic has exasperated the opioid epidemic and the urgency to find a way to help treat people who are suffering from substance use disorders is more crucial than ever.\u201d<\/p>\n

Research reported in this publication was supported by NIDA of the NIH under Award Number UG3DA047925. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.<\/p>\n

\n About BioCorRx<\/strong>\n <\/p>\n

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx\u2019s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx\u2122 Weight Loss Program is also a medication assisted weight loss program; please visit\u00a0www.uncraverx.com<\/a>\u00a0for more information on UnCraveRx\u2122. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit\u00a0www.BioCorRx.com<\/a>.<\/p>\n

\n Safe Harbor Statement<\/strong>\n <\/p>\n

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.<\/p>\n

\n BioCorRx Inc.<\/strong>\n <\/p>\n

investors@BioCorRx.com<\/p>\n

714-462-4880<\/p>\n

\n Investor Relations:<\/strong>\n <\/p>\n

Crescendo Communications, LLC<\/p>\n

(212) 671-1020 x304<\/p>\n

bicx@crescendo-ir.com\u00a0\u00a0<\/p>\n

\n Media Contact:<\/strong>\n <\/p>\n

CMW Media<\/p>\n

(858) 264-6600<\/p>\n

biocorrx@cmwmedia.com<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (\u201cBioCorRx\u201d or the \u201cCompany\u201d), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a clinical trial of BICX104, a naltrexone pellet implant for the treatment of Opioid Use Disorder (OUD). During prior nonclinical studies, several variations of BICX102 were evaluated and the current variation, BICX104, was selected for advancement to the IND stage. BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed in partnership with the National Institutes of Health (NIH) and the National … <\/p>\n

Continue reading “BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-475360","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (\u201cBioCorRx\u201d or the \u201cCompany\u201d), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a clinical trial of BICX104, a naltrexone pellet implant for the treatment of Opioid Use Disorder (OUD). During prior nonclinical studies, several variations of BICX102 were evaluated and the current variation, BICX104, was selected for advancement to the IND stage. BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed in partnership with the National Institutes of Health (NIH) and the National … Continue reading "BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-13T12:03:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone\",\"datePublished\":\"2021-04-13T12:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/\"},\"wordCount\":768,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/\",\"name\":\"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==\",\"datePublished\":\"2021-04-13T12:03:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/","og_locale":"en_US","og_type":"article","og_title":"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone - Market Newsdesk","og_description":"ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (\u201cBioCorRx\u201d or the \u201cCompany\u201d), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that the Company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a clinical trial of BICX104, a naltrexone pellet implant for the treatment of Opioid Use Disorder (OUD). During prior nonclinical studies, several variations of BICX102 were evaluated and the current variation, BICX104, was selected for advancement to the IND stage. BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed in partnership with the National Institutes of Health (NIH) and the National … Continue reading \"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-13T12:03:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone","datePublished":"2021-04-13T12:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/"},"wordCount":768,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/","name":"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==","datePublished":"2021-04-13T12:03:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNTgwOSM0MTE3OTUxIzUwMDAzMTgwMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocorrx-announces-submission-of-ind-application-to-the-fda-for-bicx104-implantable-naltrexone\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=475360"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475360\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=475360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=475360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=475360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}